Previous 10 | Next 10 |
The following list reflects actual dividend paying stocks that I hold in my personal portfolio: Barings BDC, Inc. ( BBDC ), BlackRock Capital Investment ( BKCC ), Blueknight Energy Partners - PFD Units ( BKEPP ), BlackRock Income Trust ( BKT ), BlackRock Enhanced Equity Dividend Trust ( BDJ ),...
Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phas...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the rise again last week, increasing from 3,602.55 points on Monday’s (November 25) open to 3,755.88 points as of 1:00 p.m. EST on Friday (November 29). On Wednesday (November 27), Verrica Pharmaceuticals (NASDAQ: VRCA ) revea...
Image source: The Motley Fool. ObsEva SA (NASDAQ: OBSV) Q3 2019 Earnings Call Nov 11, 2019 , 2:00 p.m. ET Operator Continue reading
Gainers: DRTT +7.9% . EGO +3.2% . AU +1.9% . OBSV +1.7% . More news on: Eldorado Gold Corporation, AngloGold Ashanti Limited, ObsEva SA, Stocks on the move, Read more ...
Dermira (NASDAQ: DERM ) +29% on apparent reaction to AnaptysBio's etokimab flop in a mid-stage atopic dermatitis study. More news on: Dermira, Inc., ObsEva SA, Sientra, Inc., Stocks on the move, Read more ...
CdbMD (NYSEMKT: YCBD ) initiated with Neutral rating and $3.40 (15% downside risk) price target at Cantor Fitzgerald. More news on: cbdMD, Inc., CV Sciences, Inc., Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
ObsEva SA (NASDAQ: OBSV ) is down 24% premarket on light volume in reaction to its announcement that lead drug nolasiban failed to achieve the primary endpoint in a Phase 3 clinical trial, IMPLANT4 , aimed at demonstrating that a single oral dose increased the pregnancy rate i...
ObsEva (NASDAQ: OBSV ): Q3 GAAP EPS of -$0.63 beats by $0.19 . Cash and cash equivalents of $91M Press Release More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news,
– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET – ...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...